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Abstract
Avian influenza A H5N1 is a virus with pandemic potential. Mucosal vaccines are attractive as they have the potential to
block viruses at the site of entry, thereby preventing both disease and further transmission. The intranasal route is safe for
the administration of seasonal live-attenuated influenza vaccines, but may be less suitable for administration of pandemic
vaccines. Research into novel mucosal routes is therefore needed. In this study, a murine model was used to compare
sublingual administration with intranasal and intramuscular administration of influenza H5N1 virosomes (2 mg
haemagglutinin; HA) in combination with the mucosal adjuvant (39,59)-cyclic dimeric guanylic acid (c-di-GMP). We found
that sublingual immunisation effectively induced local and systemic H5N1-specific humoral and cellular immune responses
but that the magnitude of response was lower than after intranasal administration. However, both the mucosal routes were
superior to intramuscular immunisation for induction of local humoral and systemic cellular immune responses including
high frequencies of splenic H5N1-specific multifunctional (IL-2+TNF-a+) CD4+ T cells. The c-di-GMP adjuvanted vaccine
elicited systemic haemagglutination inhibition (HI) antibody responses (geometric mean titres $40) both when
administered sublingually, intranasally and inramuscularly. In addition, salivary HI antibodies were elicited by mucosal,
but not intramuscular vaccination. We conclude that the sublingual route is an attractive alternative for administration of
pandemic influenza vaccines.
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Introduction
The avian influenza H5N1 continues to cause zoonosis and has
the potential to cause the next pandemic. An effective H5N1
vaccine is therefore needed. In contrast to parenteral vaccines,
mucosal immunisation can provide local mucosal immunity,
which has the potential to prevent influenza infection at the
portal of entry [1,2]. This response is largely mediated by secretory
immunoglobulin (Ig) A (sIgA), which is able to neutralise
pathogens (Reviewed in [3]). It has also been shown that sIgA
antibodies are more cross-reactive towards different strains of
influenza than IgG [4,5]. Furthermore, mucosal vaccines over-
come the use of needles, and are thus attractive for use in
developing countries. The intranasal (IN) route has been
extensively studied [6,7,8,9,10] and is safely used for the
administration of seasonal live-attenuated influenza vaccines in
humans (Reviewed in [11]). In contrast, IN vaccination with
Escherichia coli heat-labile toxin (LT) adjuvanted influenza viro-
somes significantly increased the risk of Bell’s palsy [12]. Later it
was discovered that this was probably due to the adjuvant, as
another IN formulation (not virosomes) formulated with an LT-
derived molecule was also associated with Bell’s palsy [13].
Furthermore, IN vaccination has been shown to redirect vaccine
antigen and adjuvant components to the central nervous system
(CNS) of mice [14,15,16]. These findings have prompted
exploration of alternative mucosal vaccine routes, particularly for
administration of adjuvanted influenza vaccines. The sublingual
(SL) route has been used for decades to treat angina [17] and has
more recently been investigated for allergen desensitisation
therapy [18,19] and administration of vaccines against various
bacterial and viral diseases [20,21,22,23]. An adjuvanted seasonal
influenza H1N1 vaccine (whole inactivated A/PR/8) has also
proved effective when administered sublingually to mice [15].
Since exposure to H1N1 viruses occurs continually, H1N1
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vaccines rarely require adjuvantation to elicit protective immunity.
In contrast, efficacious adjuvants are needed to protect the
unprimed population against novel influenza subtypes.
In this study we therefore aimed to evaluate the SL route for
vaccination against potentially pandemic influenza strains such as
avian influenza H5N1. In addition, we compared the immune
responses following SL vaccination with the normal routes for
influenza vaccines (intramuscular (IM) and IN). We found that SL
vaccination of mice with H5N1 virosomes induces both local and
systemic humoral and cellular immune responses. Furthermore, by
combining the virosomes with a promising mucosal adjuvant, the
bacterial second messenger c-di-GMP, the SL vaccine response
was boosted even further, as illustrated by high frequencies of
spleen-derived multifunctional (IL-2+TNF-a+) CD4+ T cells in
addition to seroprotective (geometric mean titres $40) haemag-
glutination inhibition (HI) antibody responses. In contrast to the
IM route, both IN and SL administration induced local IgA
antibodies and a salivary HI response, which could potentially
neutralise influenza virus at the portal of entry. These results
support further investigation of the SL route for administration of
vaccines against potentially pandemic influenza strains and suggest
that c-di-nucleotides might be attractive candidate adjuvants for
developing mucosal influenza vaccines.
Materials and Methods
Vaccine and Adjuvant
Inactivated influenza virosomal vaccine (Crucell, the Nether-
lands) was produced as previously described [24], using the reverse
genetics seed virus (NIBRG-14), which was derived from a
reassortment between A/Vietnam/1194/2004 (H5N1) and A/
Puerto Rico/8/34 (H1N1) (The National Institute for Biological
Standards and Control (NIBSC), UK) [25]. The virosomes contain
the surface haemagglutinin (HA) and neuraminidase proteins
embedded in a lipid membrane with no internal proteins. The c-
di-GMP adjuvant was synthesized [26,27] and purified as
described previously [10].
Mice
Female BALB/c mice (six to eight weeks old) were purchased
from Charles River laboratories (Sulzfeld, Germany) and housed
according to Norwegian National regulations. The study was
approved by the Norwegian Animal Research Authority (FDU,
ID: 20102742) and conducted according to the Norwegian Animal
welfare Act.
Vaccination and sampling
Mice were divided into groups of six animals and vaccinated IN,
IM or SL with two doses (21 days apart) of virosomal influenza A
H5N1 NIBRG-14 vaccine (2 mg of HA) with (+) or without (2) c-
di-GMP (7.5 mg) adjuvant. Additionally, one group (mock)
consisted of six mice which received only the c-di-GMP adjuvant
(7.5 mg) by the IN route. IM vaccination was performed by
injecting 50 ml into the quadriceps muscles of the hind leg. The
mucosally vaccinated mice were deeply anaesthetised by subcu-
taneous (s.c.) administration of 160 ml of a ketamine (10 mg/ml)
and xylaxine (1 mg/ml) mixture. For IN vaccination, the mice
were placed in supine position and 3.5 ml of vaccine was
administered drop-wise to each nostril. SL vaccination was
conducted as described previously [15] by holding the mice in a
vertical head-up position and administering 7 ml of vaccine under
the tongue. Subsequently, the mice were immediately placed in
anteflexion for at least 20 minutes to prevent swallowing of the
vaccine. An overview of vaccination and sampling schedules is
found in figure 1.
To measure local and systemic influenza-specific antibody
responses, blood and nasal washes (flushing twice with 350 ml
phosphate buffered saline (PBS)+0.05% bovine serum albumin)
were collected on days 7, 21, 35 and 42. In addition, saliva was
collected on day 42 by intraperitoneal injection of pilocarpine
(0.8 mg/g) to anaesthetised mice (120 ml of a ketamine (10 mg/ml)
and xylaxine (1 mg/ml) mixture s.c.). Mononuclear cells were
isolated from spleens using LymphoprepTM (Axis-Shield, Oslo) as
previously described [28] and resuspended in lymphocyte medium
(RPMI 1640 containing L-glutamine and supplemented with
0.1 mM non-essential amino acids, 10 mM Hepes pH 7.4, 1 mM
sodium pyruvate, 50 mM ß-mercapto ethanol, 100 IU/ml peni-
cillin, 100 mg/ml streptomycin, 0.25 mg/ml fungizone and 10%
foetal calf serum (FCS)) before use in the cytokine detection and
flow cytometry assays.
Influenza-specific antibodies
The influenza-specific serum, nasal wash and salivary IgA and
IgG in addition to serum IgG1 and IgG2a antibodies were
quantified using an ELISA assay, as previously described [29,30]
by coating with the NIBRG-14 H5N1 virosomes or Pandemic
H1N1 (pH1N1) 2009 whole virus (A/California/7/2009) (2 mg/
ml) (kindly provided by NIBSC, UK). The influenza-specific
antibody concentrations were calculated using IgA, IgG, IgG1 and
IgG2a standards and linear regression of the log-transformed
readings.
Figure 1. Vaccination scheme and sampling overview. BALB/c mice received two doses (2 mg HA) three weeks apart (Days 0 and 21) of
virosomal influenza A/Vietnam/1194/2004 (H5N1) NIBRG-14 vaccine intramuscularly (IM), sublingually (SL) or intranasally (IN) with or without c-di-
GMP adjuvant (7.5 mg). An additional group (mock) received PBS and c-di-GMP intranasally. Peripheral blood (PB) and nasal washes (NW) were
collected at days 7, 21 and 35 post first immunisation. NW, cardiac blood (CB), saliva and spleens were collected on the day of sacrifice (Day 42).
doi:10.1371/journal.pone.0026973.g001
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Haemagglutination inhibition
Sera and saliva from day 42 were tested for H5N1 (NIBRG-14)
HI antibodies by standard methods using a 0.7% v/v turkey
erythrocyte suspension. To remove non-specific inhibitors, sera
and saliva were treated 1:5 and 1:2, respectively with receptor-
destroying enzyme (RDE; Seiken, Japan) overnight, before heat-
inactivation (56uC, 30 min). Sera and saliva samples were added
to 96-well v-bottomed microtiter plates at a starting dilution of
1:10 and 1:4 respectively. The serum and saliva HI titres are
expressed as the reciprocal of the highest dilution at which 50%
haemagglutination was inhibited. A surrogate correlate of
protection was extrapolated from seasonal vaccination in
humans, using a titre $40 to indicate seroprotection [31] and
negatives were assigned a titre of 5 and 2 for serum and saliva,
respectively.
Cytokine detection
Cytokine secretion was investigated on day 42. To this end,
mononuclear cells from spleens (106 per well) were incubated
(37uC, 5% CO2) for 72 hours in 200 ml of lymphocyte medium
containing 2.5 mg HA/ml of virosomal influenza NIBRG-14
H5N1 antigen or medium alone. After incubation, the superna-
tants were stored at 280uC until used. The Bio-plex (Bio-rad,
USA) cytokine kits were used according to the manufacturer’s
instructions to quantify cytokines of the T helper 1 (Th1) (IFN-c,
IL-2), Th2 (IL-4, IL-5 and IL-10) and Th17 (IL-17) subsets. The
cytokine concentrations for each individual mouse were calcu-
lated by subtracting the basal release (concentrations in
supernatants from cells incubated with lymphocyte medium
alone) from the concentrations in supernatants of cells stimulated
with H5N1 influenza antigen. The cut-off point in the assay was
10 pg/ml.
CD4+ Th1 cell responses
Mononuclear cells (106 cells per well) from spleens were
incubated (37uC, 5% CO2) overnight in 200 ml lymphocyte
medium containing 2.5 mg/ml HA of virosomal influenza
NIBRG-14 H5N1 antigen (Crucell, The Netherlands) or pan-
demic H1N1 (pH1N1) A/California/7/2009-like split virus
(X179a, GlaxoSmithKline, Belgium), 2 mg/ml anti-CD28 (Phar-
mingen, USA) and 10 mg/ml Brefeldin A (BD Biosciences, USA).
The basal cytokine production was determined by incubating
splenocytes from vaccinated mice in the same medium but without
antigen and the percentages of cytokine positive cells were
subtracted from the influenza-stimulated cells. As positive controls,
cells were incubated in medium containing the mitogens phorbol
myristate acetate (10 ng/ml) and ionomycin (250 ng/ml). Subse-
quently, cells were stained for CD3, CD4, CD8, IFN-c, IL-2 and
TNF-a (BD Biosciences, USA) using the BD Cytofix/Cytoperm
kit according to the manufacturer’s instructions and as previously
described [32]. The cells were resuspended in PBS containing 5%
FCS and 0.1% sodium azide and light emission was measured by
BD FACSCanto flow cytometer (acquiring at least 36105 cells per
sample). Data were analyzed using FlowJo v8.8.6 (Tree Star,
USA), Pestle v1.6.2 and SPICE v5.1 (Mario Roederer, Vaccine
Research Centre, NIH, USA) and multifunctional CD4+ Th1 cells
were identified as previously described [30,32,33]. T cells were
classified based on cytokine IFN-c, IL-2 and TNF-a secretion as
single producers (one cytokine), double producers (two cytokines)
and triple producers (all three cytokines). In addition, the
percentages of CD4+ cells producing non-overlapping permuta-
tions of the analyzed cytokines were summed to quantify each
mouse’s total frequency of influenza specific CD4+ Th1 cells.
Memory B cells
Memory B cells were detected as described previously [34] with
the following modifications. Isolated splenic mononuclear cells
were seeded in 24-well plates at 56105 cells/well in 1 ml
lymphocyte medium containing 0.1 mg/ml pokeweed mitogen
(Sigma-Aldrich, USA) and 0.001% heat-killed, formalin-fixed
Staphylococcus aureus Cowan I strain (Merck Chemicals, USA)
for 6 days at 37uC, 5% CO2. Splenocytes were incubated likewise
in the absence of mitogens to substantiate the detection of memory
B cells and not plasma cells. ELISPOT plates (MSHAN45,
Millipore, USA) were coated with 2 mg/ml of the NIBRG-14
H5N1 virosomes or 2 mg/ml of goat anti-mouse IgG (Southern
Biotech, USA) in sterile PBS and 2.56105 cells/ml lymphocyte
medium were added and incubated for 16 hours at 37uC, 5%
CO2. The plates were developed with biotin-conjugated goat anti-
mouse IgG (Southern Biotech), extravidin peroxidase (Sigma-
Aldrich) and TMB-H peroxidase (Moss, inc., USA). The spots
were counted using an ImmunoscanTM reader (CTL-Europe,
Germany) and spots in wells with non-stimulated cells were
subtracted from corresponding wells with mitogen-stimulated cells.
The data show the percentage of H5N1-specific memory B-cells of
the total IgG producing memory B-cell response as suggested
previously [34].
Proliferation
Poliferation was measured by thymidine incorporation in
splenocytes isolated three weeks after the second vaccine dose.
Cells were diluted (107 cells/ml) in lymphocyte medium and
stimulated in 96-well plates with 2.5 mg/ml of virosomal H5N1
antigen. As a positive control, cells were stimulated with the T-cell
mitogens phorbol myristate acetate (10 ng/ml) and ionomycin
(250 ng/ml). A negative control of cells stimulated with lympho-
cyte medium alone was subtracted from influenza-stimulated cells.
After 72 hours, 1 mCi 3H-thymidine in 25 ml of medium per well
was added and the plates were incubated for 16 hours.
Subsequently the cells were harvested, 10 ml scintillation fluid
added and the incorporation of 3H thymidine determined by
scintillation spectroscopy.
Statistical analysis
To evaluate the potential of SL administration for delivery of
pandemic influenza vaccines, we used the IN and IM routes as
golden standards and compared the local and systemic humoral
and cellular immune responses following administration by each
route. Differences between groups were analyzed by one-way
ANOVA with Bonferroni’s adjustment (GraphPad Prism v5.0d for
Mac). Additionally, a student T-test integrated in SPICE v5.1 [35]
was used for the comparison of CD4+ T-cell frequencies. Analysis
and presentation of T-cell distributions was performed using
SPICE version 5.1, downloaded from http://exon.niaid.nih.gov/
spice [35].
Results
Sublingual H5N1 vaccination induces local and systemic
antibody responses
Mucosal vaccines should induce both local and systemic
antibody responses. We thus determined the influenza-specific
IgA and IgG antibody concentrations in local secretions and
serum after vaccination. The highest salivary IgA concentrations
were found in the groups receiving the adjuvanted vaccine and the
influenza-specific IgA concentrations were significantly higher in
the intranasal c-di-GMP adjuvanted (IN+) and sublingual c-di-
GMP adjuvanted (SL+) groups than in all other groups (p,0.001).
Sublingual Vaccination with H5N1 Virosomes
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In contrast, substantially lower concentrations of IgA were
observed in the non-adjuvanted mucosal groups and no IgA
could be measured in saliva from mice receiving the IM vaccines
(figure 2a). The c-di-GMP adjuvanted mucosal vaccines also
induced the highest influenza-specific IgA concentrations in the
nasal washes (figure 2b) with the highest concentrations observed
in the IN+ group (significantly higher than in all other groups at 14
and 21 days after the second dose, p,0.05) followed by the SL+
group. We also measured the influenza-specific pIgR concentra-
tions in nasal washes and saliva by ELISA to confirm that the IgA
was locally produced (sIgA) rather than a transudate from serum.
None of the groups vaccinated with the virosomes alone or the
intramuscular c-di-GMP adjuvanted (IM+) group had detectable
pIgR levels in nasal washes. In contrast, pIgR was detected in both
the SL+ and IN+ groups and a significant correlation between IgA
and pIgR concentrations was observed (data not shown).
Influenza-specific salivary IgG was detected in all vaccinated
groups and the highest concentrations were observed in the IN+
group (significantly higher than the non-adjuvanted groups,
p,0.01), followed by the SL+ and IM+ groups (figure 2c). The
c-di-GMP adjuvant enhanced the salivary IgG responses irrespec-
tive of the route of administration as observed by higher mean
concentrations (.140 ng/ml) in the IM+, SL+ and IN+ groups as
compared to their non-adjuvanted counterparts (,20 ng/ml).
The highest systemic IgA responses were also found in the c-di-
GMP adjuvanted mucosal vaccine groups. Thus, significantly
higher IgA concentrations were found in the IN+ (p,0.05
throughout the study) and SL+ groups (p,0.05 at 14 days after
the second dose) as compared to all other groups (figure 3a).
Systemic IgA responses were observed already at day seven after
the first dose in the SL+ (23 ng/ml) and IN+ (45 ng/ml) groups. In
contrast, the highest serum IgG concentration (3.5 mg/ml) was
seen in the IM+ group at seven days after the first immunisation
(significantly higher than all other groups, p,0.05) (figure 3b).
However, after the second dose the IN+ group showed the highest
serum IgG response, being significantly higher (p,0.01) than in all
other groups. We then continued to analyse the capability of the
vaccine to induce cross-reactive antibody responses towards a
heterosubtypic influenza strain, pH1N1 (figure S1). Only low
concentrations of pH1N1-specific antibodies were observed when
the virosomes were administered alone. However, the c-di-GMP
adjuvanted vaccine induced systemic pH1N1-specific IgG re-
sponses by all three routes (figure S1a). In addition, local pH1N1-
specific IgA responses were induced when the vaccine was
administered mucosally (figure S1b) and the highest concentra-
tions were observed when the vaccine was given IN (significantly
higher than all but the SL+ group, p,0.001).
Local and systemic antibodies capable of
haemagglutination inhibition are induced by sublingual
H5N1 vaccination
Since the virosomal vaccine induced antibody responses when
administered by the SL route, we continued to evaluate the
functionality of the local and systemic antibodies in the HI assay.
Sera isolated from cardiac blood at day 42 were tested for HI
antibodies against the homologous NIBRG-14 strain. HI titers
$40 were regarded as indicative of protection, although this
surrogate correlate of protection is only established for seasonal
influenza vaccines in man. Groups vaccinated with virosomes
alone had lower geometric mean titres (GMT) than their
respective adjuvanted groups but in the IM- group, all mice had
HI-titres $40 (GMT = 70). The c-di-GMP adjuvant enhanced the
HI response, and all adjuvanted groups obtained HI GMT$40 by
all administration routes (figure 4a). However, one mouse in the
SL+ group did not obtain an HI antibody response and this mouse
also responded poorly, particularly in the other antibody assays.
Comparing the different routes of administration, it was found that
the IN+ group had the highest HI titres (GMT = 550), followed by
the IM+ (GMT = 350) and the SL+ (GMT = 115) groups. Thus,
when the virosomes were given alone, only the IM route elicited
seroprotective HI titres, whilst the virosomes in combination with
c-di-GMP adjuvant induced protective HI GMT by all the
evaluated routes of administration.
As a measure of functionality of the local mucosal antibody
response, we tested saliva samples for HI antibodies against the
vaccine strain (NIBRG-14). The IN+ group had the highest HI
GMT (GMT = 15) in saliva followed by the SL+ group
(GMT = 10) (figure 4b). Among the non-adjuvanted groups, only
the SL2 group had a response (GMT = 3), whereas no salivary HI
antibody responses were observed in the intramuscular or control
groups.
Sublingual H5N1 vaccination with c-di-GMP adjuavnted
virosomes induces a balanced Th1/2 profile and Th17
responses
Pandemic influenza vaccines should preferentially activate both
Th1 (IL-2, IFN-c and TNF-a) and Th2 subsets (IL-4, IL-5, and
IL-10) of T helper cells, since both are important for elimination of
influenza virus from the host [36]. To examine the effect of SL
vaccination on the polarisation of CD4+ T-cell responses,
mononuclear cells from spleens were stimulated ex vivo for
72 hours with the NIBRG-14 virosomes and the supernatant
was analysed for production of cytokines. Generally, low levels of
Th1 cytokines were produced in the non-adjuvanted groups,
whilst adjuvantation with c-di-GMP markedly enhanced the
cytokine responses (figure 5a, b and c). Thus, all the adjuvanted
groups produced IL-2, whilst the only IL-2 producing non-
adjuvanted group was the SL2 group (figure 5a). Similarly, high
concentrations of IFN-c were produced in the SL+ (mean of
12 ng/ml), IN+ (mean of 34 ng/ml) and IM+ (mean of 5 ng/ml)
groups as compared to the non-adjuvanted groups (mean
,0.6 ng/ml for all groups) (figure 5b). When comparing the
routes of administration, we found that the mucosal routes (IN and
SL) induced a higher production of all the Th1 cytokines
measured than the IM route. In contrast, low levels of the Th2
cytokines IL-4, IL-5 and IL-10 were found in the IN+ and SL+
groups as compared to the IM- and and IM+ groups (figure 5d, e
and f). Since we have previously found that IN influenza
vaccination induces IL-17 [37,38], we analysed if IL-17 would
also be produced by SL vaccination. Indeed, IL-17 was produced
by both SL and IN vaccinated mice, whilst IM vaccination did not
induce an IL-17 response.
To further substantiate the differences in Th profiles observed
between the SL route and the IM and IN routes, we measured
the IgG2a/IgG1 ratio in serum collected two weeks after the last
of two immunisations. For the IgG subclasses (IgG1 and IgG2a),
all the non-adjuvanted groups induced a Th2 skewed response
indicated by a predominant production of IgG1 (figure 6a and
b). In contrast, inclusion of the c-di-GMP adjuvant enhanced the
production of IgG2a antibodies and both the SL+ and IN+
groups had an IgG2a/IgG1 ratio .1, whereas the IM+ group
had a ratio,1. Thus, the cytokine profiling and IgG subtype
analysis suggest that vaccination with the c-di-GMP adjuvanted
virosomes IN and SL elicits a predominant Th1 and Th17
response, whilst IM vaccination with the c-di-GMP adjuvanted
virosomes or administration of the virosomes alone induces a
Th2 polarisation.
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Figure 2. Only SL and IN vaccination induces IgA in the local mucosa. The local influenza-specific IgA antibody concentrations were
measured in the saliva and nasal washes. a) The concentrations of IgA in the saliva three weeks after the second immunisation. b) The kinetics of the
IgA responses in the nasal washes (NW). c) The local influenza-specific IgG concentrations in saliva. Each bar represents mean antibody concentration
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Mucosal administration of the c-di-GMP adjuvanted
virosomes induces high frequencies of homologous
(H5N1) and heterologous (pH1N1) influenza-specific
CD4+Th1 cells
CD4+ T cells expressing a multifunctional polarisation in the
cytokines produced have been shown to be a correlate of
protection against bacterial and protozoan diseases [32,39]. We
have previously found that high frequencies of multifunctional
CD4+ T cells are induced when the NIBRG-14 virosomes are
administered in combination with the saponine based Matrix
MTM adjuvant [30,37]. Here we assessed the ability of the c-di-
GMP adjuvanted virosomes to induce multifunctional CD4+ Th1
cells (concurrently producing two or three of the cytokines IL-2+,
IFN-c+ and TNF-a+) when co-administered by the SL route. To
this end, mononuclear cells from spleens were isolated three weeks
after the second immunisation and stimulated in vitro with the
virosomal H5N1 vaccine (NIBRG-14). Subsequently the cells were
stained for CD3 and CD4 and intracellularly for IL-2, IFN-c and
TNF-a. Only low levels of H5N1-specific cytokine producing cells
were detected in the non-adjuvanted groups and no significant
differences were observed between the non-adjuvanted groups
(data not shown). In contrast, when the virosomes were combined
with c-di-GMP, high frequencies of IL-2, IFN-c and TNF-a
producing cells were induced (figure 7). Overall, the IN+ group
had the highest frequencies of H5N1-specific cytokine producing
CD4+ Th1 cells followed by the SL+ group (figure 7). Thus, the
IN+ group had the highest frequencies of CD4+ T cells
simultaneously producing all three of the measured cytokines
(significantly higher than the IM+ and SL+ groups, p,0.05), whilst
+ SEM. *, ** and *** indicate statistically significant differences between groups (p,0.05, p,0.01 and p,0.001 respectively, One-way ANOVA with
Bonferroni’s correction for multiple group comparison). N.D=not detected. BALB/c mice were vaccinated intramuscularly (IM), sublingually (SL) or
intranasally (IN) with (+) or without (2) c-di-GMP adjuvant. An additional group received a mock vaccine (C) of c-di-GMP alone administered IN.
doi:10.1371/journal.pone.0026973.g002
Figure 3. Systemic antibody kinetics following immunization. The a) IgA and b) IgG serum influenza-specific antibody concentrations were
measured at 7 and 21 days after the first vaccine dose and 14 and 21 days after the second dose. Each bar represents mean antibody concentration +
SEM. * and ** indicate statistically significant differences between groups (p,0.05 and p,0.01 respectively, One-way ANOVA with Bonferroni’s
correction for multiple group comparison). Groups of six mice were vaccinated intramuscularly (IM), sublingually (SL) or intranasally (IN) with a
virosomal H5N1 vaccine (NIBRG-14) with (+) or without (2) c-di-GMP adjuvant. An additional group received a mock vaccine (C) of c-di-GMP alone
administered IN.
doi:10.1371/journal.pone.0026973.g003
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no significant differences were found between the IM+ and SL+
groups in terms of triple cytokine producing cells. CD4+ T cells
simultaneously producing IL-2 and TNF-a dominated the double
cytokine producing cell response and the highest cell frequencies
were found in the IN+ and SL+ groups (both significantly higher
than the IM+ group, p,0.01). In contrast, a low frequency of cells
in the SL+ group produced IFN-c and TNF-a or IFN-c and IL-2
simultaneously. The single-cytokine producing cells synthesised
mainly TNF-a and the highest frequencies of these cells were
observed in the IN+ (significantly higher than in the IM+ and SL+
groups, p,0.01) and SL+ (significantly higher than the IM+ group,
p,0.05) groups. The proportions of triple producers, double
producers and single producers are shown in the pie charts
(figure 7). When focusing on the distribution of the single, double
and triple producers, the IM+ group had the largest proportion of
triple producers with approximately 30% of the CD4+ T cells in
the IM+ group producing all three cytokines. In contrast, the
majority of CD4+ T cells in the SL+ and IN+ groups were double
producers.
It has previously been reported that CD4+ T cells can cross-
react between influenza virus subtypes [40,41,42,43]. We thus
continued to investigate if SL vaccination with the c-di-GMP
adjuvanted virosomal vaccine would induce hetero-subtypic cross-
reactive CD4+ T cell responses, by stimulating with pH1N1
antigen (figure 8). All permutations of the produced cytokines were
summed to measure the total frequency of influenza specific CD4+
Th1 cells. Similarly to homologous stimulation, pH1N1 stimula-
tion induced the highest frequencies of cytokine producing CD4+
T cells in the groups receiving the c-di-GMP adjuvanted vaccine
IN (significantly higher than all other groups, p,0.001) and SL
(significantly higher than all other groups except the IN+, p,0.01)
illustrating that hetero-subtypic CD4+ Th1 cell responses can be
activated by SL administration. Thus, although the c-di-GMP
adjuvanted vaccine induced CD4+ Th1 cell responses when
administered IM, the frequencies of homologous and hetero-
subtype influenza-specific CD4+ Th1 cells were significantly
higher upon IN and SL administration.
Discussion
Mucosal vaccination against H5N1 virus has many potential
benefits, such as limiting transmission, inducing cross-reactive
immune responses that could prevent disease caused by drifted
strains [4,5] and being suitable for use in low-income countries.
Numerous studies have highlighted the need for an effective
adjuvant to elicit seroprotective responses against H5N1 viruses
(Summarised in [44]). Although IN vaccination against influenza
has proven highly effective, the use of adjuvants poses a problem
since adjuvanted IN administered vaccines were associated with
the facial nerve disease Bell’s palsy [12,13]. Thus, alternative
mucosal routes for H5N1 vaccines are highly desirable. In contrast
to the olfactory epithelium, which is in close proximity to the
brain, the SL route is anatomically more distant, thus minimising
the risk of neurological side effects, whilst providing local mucosal
respiratory immunity. In this study we present a head-to-head
comparison of the immune responses induced by influenza
vaccination through the IM, IN and SL routes and show that
H5N1 virosomes in combination with a novel effective mucosal
adjuvant can be highly immunogenic when administered by the
SL route. Virosomes are potent stimulators of mucosal immunity
(Reviewed in [45]) and SL vaccination with the c-di-GMP
adjuvanted H5N1 virosomes induced both local and systemic
antibody responses and high frequencies of influenza-specific
homo- and hetero-subtypic CD4+ Th1 cells. These responses
appeared qualitatively similar to when the vaccine was adminis-
tered IN, but were reduced in magnitude. Likely explanations for
the differences in magnitude could be that SL administration of
vaccine antigen has induced an unintended tolerogenic response,
although the low concentration of IL-10 does not support this, or
that the vaccine components have been subjected to enzymatic
degradation in the saliva before absorption. Another possibility is
that the antigen uptake and processing under the tongue is
Figure 4. The c-di-GMP adjuvanted vaccine induced both
systemic and local haemagglutination inhibition responses
when administered mucosally. Haemagglutination inhibition (HI)
antibodies were measured at day 42 in a) serum. The data show the
response of each individual mouse and the geometric mean titres
695% confidence interval. The dotted line represents an HI titre of 40.
b) The local HI response was measured in saliva at day 42 after
intraperitoneal injection of pilocarpine and collection of saliva. To
obtain enough sample volume, the salivary HI assay was conducted on
pooled saliva samples. The data show the geometric mean titres +95%
confidence interval of three independent experiments. * and ** indicate
statistically significant differences between groups (p,0.05 and 0.01
respectively, One-way ANOVA with Bonferroni’s correction for multiple
group comparison). The mice (six per group) were vaccinated with the
virosomal H5N1 vaccine (NIBRG-14) alone (2) or in combination with (+)
c-di-GMP adjuvant by the intramuscular (IM), sublingual (SL) or
intranasal (IN) route. One additional group received a mock vaccine
(C) of c-di-GMP administered alone by the IN route.
doi:10.1371/journal.pone.0026973.g004
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different than of the nose, which is supported by a previous study
showing that the nasal associated lymphoid tissues may be a
superior mucosal site as compared to other mucosal associated
lymphoid tissues [46]. Finally, deglutition of vaccine components
cannot be excluded and our studies suggest that c-di-GMP exhibits
reduced activity when administered orally (unpublished data).
Nonetheless, a low volume (#7 ml) was administered to minimise
this risk [15]. We have previously evaluated a c-di-GMP
adjuvanted plant produced H5 HA1 vaccine for IN and IM
administration. Compared to this vaccine candidate, IM admin-
istration of the virosomes offered significantly higher humoral and
cellular responses both when administered alone and in combi-
nation with c-di-GMP [47]. However, when comparing the two
vaccine candidates for IN administration we found that the
responses were of the same order of magnitude, which may suggest
that the virosomal formulation offers little advantage in terms of
inducing a mucosal immune response and illustrates the
importance of including a potent adjuvant in mucosal vaccine
formulations. In this context, we found that the STING receptor
ligand c-di-GMP [48] boosted the mucosal vaccine responses
significantly.
A previous study has shown that SL vaccination with an
inactivated whole H1N1 strain elicits protection against lethal viral
challenge with influenza [15]. We have not evaluated the
protective efficacy of SL vaccination with the c-di-GMP
adjuvanted NIBRG-14 H5N1 virosomes, but our previous results
showed that two IM doses (1 mg HA) of the NIBRG-14 H5N1
virosomal vaccine alone protected BALB/c mice from lethal viral
challenge with highly pathogenic avian influenza (HPAI) H5N1
[37]. In the current study we found that the same vaccine, when
combined with c-di-GMP and administered by the SL route,
induces stronger humoral and cellular immune responses than the
virosomal vaccine alone given IM. Extrapolating from our
previous results, we can therefore predict that SL vaccination of
the c-di-GMP adjuvanted vaccine would probably also protect
mice from challenge with HPAI. This is supported by the finding
Figure 5. The adjuvanted SL and IN vaccines induced the highest Th1 and Th17 cytokine concentrations. BALB/c mice were vaccinated
intramuscularly (IM), sublingually (SL) or intranasally (IN) with virosomal H5N1 vaccine (NIBRG-14) alone (2) or with (+) c-di-GMP adjuvant. An
additional group received a mock vaccine of c-di-GMP administered alone IN (C). Splenocytes were isolated three weeks after the second
immunisation and incubated for 72 hours with 2.5 mg/ml of H5N1 virosomal NIBRG-14 before analysis by Bio-plex for a) IL-2, b) IFN-c, c) TNF-a, d) IL-
4, e) IL-5, f) IL-10 and g) IL-17. The cytokine concentrations for each mouse were calculated by subtracting the basal release of unstimulated samples
from that of stimulated samples. Each bar represents mean values from six mice and error bars indicate SEM. *, ** and *** indicate statistically
significant differences between groups (p,0.05, p,0.01 and p,0.001 respectively, One-way ANOVA with Bonferroni’s correction for multiple group
comparison).
doi:10.1371/journal.pone.0026973.g005
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of protective serum HI antibody responses (HI titres$40) in five of
six mice the SL group three weeks after the second immunisation
(figure 4a). Furthermore, SL vaccination with the c-di-GMP
adjuvanted vaccine induced salivary HI antibodies as opposed to
the IM route (figure 4b), although it remains unclear if these levels
of locally secreted antibodies would be sufficient to prevent
transmission of influenza [49]. Notably, a salivary surrogate
correlate of protection would likely be lower than in the serum (HI
titre $40), because salivary antibodies should only be able to
overcome the initial viral load, whilst serum antibodies should
prevent disease despite viral replication in the respiratory tract.
The c-di-GMP adjuvanted vaccine induced local influenza-
specific IgA in the SL and IN groups, but not in the IM groups,
which confirms that parenteral vaccination induces only limited
mucosal IgA antibody-responses [1]. To substantiate that the IgA
antibodies were locally produced rather than derived by
transudation, we measured the H5N1-specific pIgR responses in
salivary secretions and found that only the mucosal routes elicited
pIgR production. In addition, we found that the concentrations of
IgA reflected those of pIgR (data not shown) as has been reported
earlier [50]. Interestingly, H5N1-specific IgG was detected in
saliva following vaccination by all routes, but it is unclear if these
antibodies are locally produced or if they originate from serum. Of
note, despite having IgG antibodies in saliva, a salivary HI
response was not measured in the IM+ group and we thus propose
that the secretory HI response is due to locally produced IgA. The
systemic IgG levels were highest in the IN+ group, whilst no
differences in IgG concentrations were observed between the IM+
and SL+ groups. To get an indication of the long-term
effectiveness of the vaccine, we measured the frequency of
memory B cells, by mitogenic stimulation of splenocytes for 6
days and subsequent ELISPOT for detection of H5N1-specific
IgG producing cells [34,51,52] and found that the mucosal
vaccines induced a superior memory B cell response to
intramuscular vaccination (figure S2a).
Influenza infection induces a predominant Th1 response
[53,54]. In contrast, inactivated influenza vaccines have been
reported to stimulate Th2-skewed responses [37,55,56]. Here we
show that the H5N1 virosomes alone induced a Th2 response
upon mucosal (SL and IN) administration (figure 6), in accordance
with our previous findings [30,37]. However, the inclusion of c-di-
GMP adjuvant resulted in a skewing of the response towards a
balanced or predominant Th1 response. This is an important
property of the c-di-GMP adjuvant [10,57], since Th1 cells are
important for recovery from influenza viral infection [36,58].
Furthermore, a Th2 response can potentially be detrimental due
to development of asthma (reviewed in [59]). IL-17, the Th17
cytokine, is elicited by IN vaccination [37,38]. It has also been
shown that SL vaccination with a bacterial antigen can induce IL-
17 [21]. Here we extend these results to include SL vaccination
Figure 6. The c-di-GMP adjuvant altered the IgG2a/IgG1 ratio towards a more Th1 skewed phenotype. Intramuscular (IM), sublingual
(SL) and intranasal (IN) administration of BALB/c mice was performed with the virosomal H5N1 vaccine (NIBRG-14) in combination with (+) c-di-GMP
adjuvant or alone (2). An additional group received a mock vaccine (C) with only c-di-GMP administered IN. a) The concentration of IgG1 and IgG2a
in the serum at two weeks after the second immunisation. Each bar represents mean antibody concentration + SEM. b) The IgG2a/IgG1 ratio
(ratios.1 and ,1 indicate a Th1 and Th2 polarised response, respectively).
doi:10.1371/journal.pone.0026973.g006
Figure 7. The c-di-GMP adjuvanted vaccine induced the
highest frequencies of influenza-specific CD4+ T-cells when
given mucosally. The CD4+ T-cell functional responses were
measured by stimulating splenocytes ex vivo with the H5N1 virosomes
before fixation, staining for IFN-c, IL-2 and TNF-a and analysis by flow
cytometry. The bars show the frequencies of CD4+ T-cells producing
any of the seven possible combinations of the measured cytokines. The
pie charts show the fraction of CD4+ T-cells within each group
producing any one, any combination of two or all three cytokines
simultaneously + SD. * and ** indicate statistically significant differences
between groups (p,0.05 and p,0.01 respectively measured by the
Student t-test). BALB/c mice were vaccinated with c-di-GMP adjuvanted
virosomal H5N1 vaccine (NIBRG-14) by the intramuscular (IM+),
sublingual (SL+) or intranasal (IN+) route.
doi:10.1371/journal.pone.0026973.g007
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against influenza and we speculate if IL-17 can be used as a
mucosal immune response signature. However, the importance of
IL-17 for influenza disease outcome remains controversial. In one
study, IL-17RA knockout mice had improved survival following
lethal influenza viral challenge as compared to wild type mice [60],
suggesting a detrimental effect of IL-17 in the course of influenza
infection. In contrast, another study showed that adoptively
transferred Th17 effector cells can protect naı¨ve mice against
lethal influenza viral challenge [61] and it was recently shown in a
mouse model that IL-17 plays a crucial role for B cell responses to
influenza H5N1 infection [62]. We have previously found that IM
vaccinated mice were protected against homologous HPAI
challenge despite not producing IL-17 upon ex vivo re-stimulation
of splenocytes [37], which suggests that IL-17 is dispensable in
terms of effective vaccination against influenza. More studies are
therefore needed to elucidate whether IL-17 has an important
function in protection against influenza disease. Interestingly, a
recent study showed that IL-17 can contribute to generation of a
Th1 response [63], which may at least in part explain why the
mucosal groups in our study showed a Th1 skewed response and
very high frequencies of H5N1 specific CD4+ Th1 cells, whilst IM
vaccination induced a Th2 polarised response and lower CD4+
Th1 cell frequencies.
The c-di-GMP adjuvanted virosomal H5N1 vaccine induced
homologous (H5N1) and hetero-subtypic (pH1N1) influenza-
specific CD4+ Th1 cells and significantly higher (p,0.01)
frequencies of CD4+ Th1 cells were produced after mucosal (IN
and SL) than IM administration (figure 8). To elucidate if overall
higher T cell responses were induced by mucosal (SL or IN) rather
than IM administration, we measured H5N1-specific proliferation
of mononuclear cells from the spleens three weeks after the second
immunisation and found no significant differences in proliferation
between these routes of immunisation (figure S2b). Interestingly,
the Th1 cell cytokine profile was dominated by double cytokine
(IL-2+TNF-a+) producing cells in the SL+ and IN+ groups, whilst a
higher proportion of triple (IL-2+TNF-a+IFN-c+) producers were
observed in the IM+ group. Similarly, we have previously found
that IM immunisation with the virosomal vaccine in combination
with Matrix MTM adjuvant elicits a higher proportion of triple
cytokine producing cells than IN vaccination [30] and that these
cells are functionally superior to single and double cytokine
producers [37]. Nevertheless, it has previously been proposed that
IL-2+TNF-a+ CD4+ T cells have a higher long-term memory
potential than IL-2+TNF-a+IFN-c+ CD4+ T cells as IFN-c
producing cells represent a highly differentiated CD4+ T cell
phenotype with a poor memory potential [64,65]. Therefore, the
optimal CD4+ T cell polarisation in terms of influenza vaccination
needs to be further investigated.
Previous studies have found that whilst IN immunisation can
redirect vaccine components to the olfactory bulbs and brain
[14,15], this is not a problem with the SL route [15] and this
makes SL vaccination a potentially safer alternative than IN
vaccination with regard to neurological side-effects. Nevertheless,
we need to highlight that the only IN adjuvants associated with
Bell’s palsy has been A–B moiety toxins and their derivatives. In
this context, it is well known that neurons display the specific
receptors for the B subunit of these toxins and that these could
facilitate retrograde homing to the CNS. Therefore, IN admin-
istration of adjuvants other than A–B moiety toxin derivatives may
not have the same potential risk. However, the association
between IN vaccination and neurological side effects may cause
a scepticism against IN vaccines in the general population and its
important to conduct extensive toxicology testing prior to the
approval of any adjuvanted IN human vaccine. In this context, we
show that the SL route is a promising alternative approach for the
delivery of vaccines against potentially pandemic influenza strains.
Particularly, the c-di-GMP adjuvanted H5N1 virosomes induces
potent local and systemic immune responses when administered by
the SL route. Therefore, we suggest further evaluation of the
efficacy of this vaccine candidate in pre-clinical ferret studies.
Figure 8. Sublingual and intranasal vaccination induces high frequencies of CD4+ T-cells cross-reactive towards pH1N1 virus. The
frequencies of influenza specific CD4+ T-cells were measured as described in figure 7 by stimulation with a) the H5N1 virosomes and b) the pH1N1 A/
California/7/2009-like virus (X179a). The bars show total frequencies of influenza-specific CD4+ T-cells (the percentages of cells producing any one or
more of the measured cytokines) + SEM. ** and *** indicate statistically significant differences between groups (p,0.01 and p,0.001 respectively,
One-way ANOVA with Bonferroni’s correction for multiple group comparison). BALB/c mice were vaccinated intramuscularly (IM), sublingually (SL) or
intranasally (IN) with virosomal H5N1 vaccine (NIBRG-14) alone (2) or in combination with (+) c-di-GMP adjuvant. An additional group received a
mock vaccine (C).
doi:10.1371/journal.pone.0026973.g008
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Supporting Information
Figure S1 The heterosubtypic local and systemic anti-
body responses towards the pandemic H1N1 2009 virus.
Cross-reactive antibodies towards the pandemic H1N1 2009 virus
(pH1N1) at two weeks after the second dose were measured by
ELISA. a) The concentrations of cross-reactive IgA antibodies
towards the pH1N1 virus in the nasal washes. b) The serum
pH1N1-specific IgG antibody concentrations. Each bar represents
mean antibody concentration+SEM. *** indicates statistically
significant differences between groups (p,0.001, One-way
ANOVA with Bonferroni’s correction for multiple group com-
parison). Groups of six mice were vaccinated intramuscularly (IM),
sublingually (SL) or intranasally (IN) with a virosomal H5N1
vaccine (NIBRG-14) with (+) or without (2) c-di-GMP adjuvant.
An additional group received a mock vaccine (C) of c-di-GMP
alone administered IN.
(EPS)
Figure S2 The c-di-GMP adjuvanted vaccine induces a
proliferative response irrespective of administration
route and the highest H5N1-specific memory B-cell
frequencies when administered mucosally. The frequency
of H5N1-specific memory B-cells (a) was measured by ELISPOT
and the proliferative response (b) was measured in splenocytes 21
days after the second dose by stimulation with H5N1 virosomes.
Each bar represents mean antibody concentration+SEM. * and **
indicate statistically significant differences between groups (p,0.05
and p,0.01 respectively, One-way ANOVA with Bonferroni’s
correction for multiple group comparison). Groups of six mice
were vaccinated intramuscularly (IM), sublingually (SL) or
intranasally (IN) with a virosomal H5N1 vaccine (NIBRG-14)
with (+) or without (2) c-di-GMP adjuvant. An additional group
received a mock vaccine (C) of c-di-GMP alone administered IN.
(EPS)
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